Secondary prevention in thrombotic antiphospholipid syndrome

被引：11
|
作者：
Pengo, V. [1 ]
Denas, G. [1 ]
Banzato, A. [1 ]
Bison, E. [1 ]
Bracco, A. [1 ]
Facchinetti, M. [2 ]
Hoxha, A. [2 ]
Ruffatti, A. [2 ]
机构：
[1] Univ Padua, Thrombosis Ctr, Dept Cardiac Thorac & Vasc Sci, I-35128 Padua, Italy
[2] Univ Padua, Rheumatol Unit, Dept Med, I-35128 Padua, Italy
来源：
LUPUS | 2012年 / 21卷 / 07期
关键词：
antiphospholipid; prevention; drugs; thrombosis; RECURRENT THROMBOSIS; THERAPY; INTENSITY; WARFARIN; RISK;
D O I：
10.1177/0961203312444773
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Secondary prevention of venous thromboembolism in antiphospholipid syndrome (APS) is usually made using vitamin K antagonists (VKAs) to maintain an international normalized ratio (INR) between 2.0 and 3.0. The optimal intensity of anticoagulation was determined in two prospective randomized controlled trials, both excluding the benefit of more intense anticoagulation. The same regimen is also recommended in patients with APS and arterial thromboembolism as aspirin does not appear to protect against recurrences. The duration of treatment is usually indefinite because of a substantial risk of recurrence. Lupus (2012) 21, 734-735.
引用
收藏
页码：734 / 735
页数：2
相关论文
共 50 条
  • [41] Circulating levels of tissue factor and the risk of thrombosis associated with antiphospholipid syndrome
    Tobaldini, Lais Quinteiro
    Arantes, Fernanda Talge
    Saraiva, Sabrina da Silva
    Mazetto, Bruna de Moraes
    Colella, Marina Pereira
    de Paula, Erich Vinicius
    Annichino-Bizzachi, Joyce
    Orsi, Fernanda Andrade
    THROMBOSIS RESEARCH, 2018, 171 : 114 - 120
  • [42] Clinical course of high-risk patients diagnosed with antiphospholipid syndrome
    Pengo, V.
    Ruffatti, A.
    Legnani, C.
    Gresele, P.
    Barcellona, D.
    Erba, N.
    Testa, S.
    Marongiu, F.
    Bison, E.
    Denas, G.
    Banzato, A.
    Jose, S. Padayattil
    Iliceto, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (02) : 237 - 242
  • [43] Antiphospholipid syndrome in terms of cardiovascular surgery
    Uyar, Ihsan Sami
    Uyar, Belkiz
    Kobak, Senol
    Okur, Faik Fevzi
    Alayunt, Emin Alp
    TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2015, 23 (01): : 191 - 198
  • [44] Antiphospholipid syndrome: Unusual clinical presentations
    Greaves, Mike
    THROMBOSIS RESEARCH, 2011, 127 : S47 - S50
  • [45] Oral anticoagulants in thrombotic antiphospholipid syndrome: Leave the old road for a new trail?
    Pengo, Vittorio
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 79 : 29 - 30
  • [46] Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases
    Signorelli, Flavio
    Nogueira, Felipe
    Domingues, Vinicius
    Mariz, Henrique Ataide
    Levy, Roger A.
    CLINICAL RHEUMATOLOGY, 2016, 35 (03) : 801 - 805
  • [47] Thrombotic antiphospholipid syndrome in a child with human immunodeficiency virus: a rare case report
    Dong, Rong-Jing
    Lei, Su-Yun
    Li, Jun
    Yang, Xin-Ping
    Li, Yu-Ye
    Zhang, Yun-Gui
    THROMBOSIS JOURNAL, 2021, 19 (01)
  • [48] Statins as an Adjunctive Antithrombotic Agent in Thrombotic Antiphospholipid Syndrome: Mechanisms and Clinical Implications
    Bucci, Tommaso
    Menichelli, Danilo
    Palumbo, Ilaria Maria
    Pastori, Daniele
    Ames, Paul R. J.
    Lip, Gregory Y. H.
    Pignatelli, Pasquale
    CELLS, 2025, 14 (05)
  • [49] Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management
    Sayar, Zara
    Moll, Rachel
    Isenberg, David
    Cohen, Hannah
    THROMBOSIS RESEARCH, 2021, 198 : 213 - 221
  • [50] Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases
    Flavio Signorelli
    Felipe Nogueira
    Vinicius Domingues
    Henrique Ataide Mariz
    Roger A. Levy
    Clinical Rheumatology, 2016, 35 : 801 - 805
12345